An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer
Latest Information Update: 18 Apr 2022
At a glance
- Drugs Nivolumab (Primary) ; Pixatimod (Primary)
- Indications Adrenocortical carcinoma; Colorectal cancer; Endometrial cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Uterine cancer
- Focus Adverse reactions
- 16 Jun 2021 Planned number of patients changed from 50 to 62.
- 16 Jun 2021 Status changed from recruiting to completed.
- 16 Nov 2018 Preliminary results (n=9 data cut off: 19, June 2018) presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics